COMMUNIQUÉS West-GlobeNewswire

HCW Biologics Announces 1-for-6 Reverse Stock Split Effective on June 30, 2026
26/06/2026
Company completed 28 consecutive trading days above $1.00 per share on June 25, 2026 Reverse stock split effectuated to ensure ongoing compliance with the Bid Price Rule and additional requirements from Nasdaq Hearings [...]
Medicenna Therapeutics Reports Fiscal Year 2026 Financial Results and Operational Highlights
26/06/2026
MDNA11, as a single agent or in combination with pembrolizumab, continues to demonstrate compelling anti-tumor activity in patients with advanced or metastatic cutaneous melanoma, endometrial cancer and gastrointestinal [...]
Readout from Legacy Ultimovacs DOVACC Phase II Trial Concludes UV1 Programme as Previously Guided
26/06/2026
Oslo, 26 June 2026 – Zelluna (OSE: ZLNA) , a company pioneering allogeneic "off-the-shelf" T Cell Receptor-based Natural Killer (TCR-NK) cell therapies for the treatment of solid cancers, today announces that the NSGO- [...]
Replimune Announces FDA Acceptance of RP1 Biologics License Application Resubmission for Advanced Melanoma
26/06/2026
FDA decision expected by August 2, 2026 WOBURN, Mass., June 26, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (NASDAQ: REPL), a clinical-stage biotechnology company pioneering the development of novel oncolytic [...]
LIXTE Joins Russell Microcap Index
26/06/2026
BOCA RATON, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), today announced its inclusion in the Russell Microcap ® Index, effective after the close [...]
Nkarta to Participate in H.C. Wainwright 4th Annual Cell Therapy Virtual Conference
26/06/2026
SOUTH SAN FRANCISCO, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Nkarta, Inc. (Nasdaq: NKTX), a clinical-stage biopharmaceutical company developing engineered natural killer (NK) cell therapies to treat autoimmune [...]
Vaxart Publishes Presentation Urging Shareholders to Vote “FOR” ALL Six of the Company’s Highly Qualified Director Nominees on the WHITE Proxy Card TODAY
26/06/2026
Details Strategic Actions Taken by the Board to Advance the Company’s Pipeline and Drive Value Creation Vaxart’s Purpose-Built Board Brings the Proven Expertise Needed to Oversee its Next Phase of Growth Dissident [...]
Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the ISTH 2026 Congress
26/06/2026
New results from HMB-002 first-in-human data validate proof of mechanism in Von Willebrand disease (VWD), elevating Von Willebrand Factor (VWF) and Factor VIII (FVIII) levels with subcutaneous dosing; multiple dose [...]
New Yorkers Celebrate Independence Through Helen Keller's Legacy at Premiere of Groundbreaking Documentary Possibilities
26/06/2026
Blind artists, educators, advocates, and creatives gather on Helen Keller's 146th birthday ahead of America's 250th anniversary NEW YORK, June 26, 2026 (GLOBE NEWSWIRE) -- As America approaches the 250th anniversary of [...]
Sienna Completes Acquisition in Greater Ottawa Area
26/06/2026
MARKHAM, Ontario, June 26, 2026 (GLOBE NEWSWIRE) -- Sienna Senior Living Inc. (" Sienna " or the " Company ") (TSX: SIA) announced today that it has completed its previously disclosed acquisition of Rockland Manor, a [...]
Opus Genetics Added to the Russell 3000®, Russell 2000® and Russell Microcap® Indexes
26/06/2026
RESEARCH TRIANGLE PARK, N.C., June 26, 2026 (GLOBE NEWSWIRE) -- Opus Genetics, Inc. (Nasdaq: IRD) (the “Company” or “Opus Genetics”), a clinical-stage biopharmaceutical company developing gene therapies to restore [...]
Standard Dental Labs Inc. Signs Letter of Intent to Acquire Additional Dental Laboratory in the Tampa Bay Region
26/06/2026
ORLANDO, Fla., June 26, 2026 (GLOBE NEWSWIRE) -- Standard Dental Labs Inc. (OTCQB: TUTH) ("SDL" or the "Company"), a rapidly growing dental laboratory consolidator focused on the Florida market, today announced that it [...]
Capricor to Present Positive Five-Year HOPE-2 OLE Data and HOPE-3 Phase 3 Results for Deramiocel in Duchenne Muscular Dystrophy at PPMD 2026 Annual Conference
26/06/2026
Deramiocel demonstrates durable skeletal and cardiac muscle benefit over five years in the HOPE-2 OLE study PUL 2.0 year-over-year decline attenuated to approximately 1 point Findings to be presented alongside [...]
CDT Highlights Sarborg's Application of Quantum Computing to Solid-Form Development
26/06/2026
NAPLES, Fla. and CAMBRIDGE, United Kingdom, June 26, 2026 (GLOBE NEWSWIRE) -- CDT Equity Inc. (Nasdaq: CDT) (“CDT” or the “Company”), today notes the announcement from Sarborg Limited regarding the expansion of its [...]
Thought Leadership & Innovation Foundation Founder Bill Oldham Launches New Book: Beyond Better Data: What Actually Changes Health Care?
26/06/2026
MCLEAN, Va., June 26, 2026 (GLOBE NEWSWIRE) -- The Thought Leadership & Innovation Foundation (TLI) proudly announces the release of Beyond Better Data: What Actually Changes Health Care? a new book by Founder and [...]
Capricor Therapeutics Announces FDA Advisory Committee Meeting to Review BLA for Deramiocel for the Treatment of Duchenne Muscular Dystrophy
26/06/2026
–Advisory Committee meeting scheduled for July 29, 2026– –Company's Biologics License Application on track with PDUFA target action date of August 22, 2026– SAN DIEGO, June 26, 2026 (GLOBE NEWSWIRE) -- Capricor [...]
CHMP recommendation advances Johnson & Johnson’s TECVAYLI®▼ (teclistamab) plus daratumumab as a potential standard of care for relapsed/refractory multiple myeloma
26/06/2026
Recommendation supported by unprecedented Phase 3 data, demonstrating that TECVAYLI ® in combination with daratumumab achieved statistically significant improvements in progression-free and overall survival versus [...]
Vivani Medical Announces Appointment of August J. Moretti to Board of Directors and Retirement of Dr. Dean Baker
26/06/2026
ALAMEDA, Calif., June 26, 2026 (GLOBE NEWSWIRE) -- Vivani Medical, Inc. (NASDAQ: VANI) (“Vivani” or the “Company”), a clinical-stage biopharmaceutical company developing miniature, ultra long-acting drug implants, today [...]
Elixirgen Therapeutics and Nippon Shinyaku Enter into an Option Agreement for the Development and Commercialization of EXG-7001 for Duchenne Muscular Dystrophy
26/06/2026
BALTIMORE, June 26, 2026 (GLOBE NEWSWIRE) -- Elixirgen Therapeutics, Inc ., a clinical-stage biotechnology company developing treatments for rare diseases and aging-associated diseases, today announced that it has [...]

Pages